ALK‑positive locally advanced lung cancer in a patient who achieved long‑term complete response with crizotinib: A case report

In the last two decades, the existence of key oncogenic alterations, such as activating mutations or chromosomal reorganization, has become crucial in the advanced stage non-small cell lung cancer (NSCLC) treatment paradigm. Among these, anaplastic lymphoma kinase (ALK) gene rearrangement is reporte...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2022-11, Vol.24 (5), Article 650
Main Authors: Emirzeoglu, Levent, Olmez, Ozgur
Format: Article
Language:English
Subjects:
Cancer therapies
Case Report
Case reports
Case studies
Chemotherapy
Crizotinib
Dosage and administration
Drug therapy
Gene mutations
Inhibitor drugs
Lung cancer
Lung cancer, Non-small cell
Lymphatic system
Lymphoma
Metastasis
Patient outcomes
Patients
Targeted cancer therapy
Tomography
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the last two decades, the existence of key oncogenic alterations, such as activating mutations or chromosomal reorganization, has become crucial in the advanced stage non-small cell lung cancer (NSCLC) treatment paradigm. Among these, anaplastic lymphoma kinase (ALK) gene rearrangement is reported in 3-7% of NSCLC cases worldwide. In patients who respond to long-term ALK therapy, treatment duration is uncertain. The present study reported a case of variant type 1 ALK-rearranged stage 3B lung adenocarcinoma that maintained a complete response for >6 years under treatment with crizotinib. As first-line treatment, crizotinib was administered twice daily (250 mg) and a complete response was confirmed after 3 months. After a complete response to crizotinib for 6 years, the treatment was stopped and the patient was followed up. Multiple brain metastases were detected during the third month of follow-up.
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2022.11587